LONDON, September 23, 2014 /PRNewswire/ --
Avillion LLP, a co-developer of late-stage pharmaceutical assets, announces the appointment of Jarrod Longcor as Chief Business Officer. In this role, Mr Longcor is responsible for structuring, negotiating and executing successful strategic alliances, co-development agreements, and financial investments, as well as providing management and strategic leadership to the organisation. He is a member of the Executive leadership team.
Mr Longcor brings to Avillion LLP over 18 years of pharmaceutical and biotech experience and was previously the Vice President of Corporate Development for Rib-X Pharmaceuticals, Inc. (now Melinta Therapeutics). In this role, he was responsible for identifying and concluding several critical collaborations for the company, including a major discovery collaboration with Sanofi Aventis with a potential value of over $700 million. Prior to Rib-X, Mr Longcor held key positions in several small to mid-sized biotech companies where he was responsible for business development and strategic planning.
Allison Jeynes-Ellis, Chief Executive Officer of Avillion, said: "It is a great pleasure to welcome Jarrod to our management team at Avillion. He brings valuable corporate development skills, experience and contacts from across the pharmaceutical industry. Our first collaborative development programme with Pfizer to conduct a global Phase 3 trial of BOSULIF® in chronic myelogenous leukemia is underway, and Jarrod coming on board enables us to intensify our efforts to complete additional co-development agreements in the coming months."
Mr Longcor holds a B.S. from Dickinson College, a M.S. from Boston University School of Medicine and an MBA from Saint Joseph's University's Haub School of Business.
A photograph of Jarrod Longcor is available on request.
Avillion LLP is a drug development company with an innovative business model focusing on the clinical development and regulatory approval of late stage pharmaceutical products. Avillion LLP offers a compelling opportunity to partner late-stage therapeutic projects for approval in the US and EU and to accelerate their availability to the market. Our objective is to enable our partners to continue to develop the drug candidates in their pipeline without increasing the burden on their P&L or cash reserves. Avillion LLP can achieve this by incurring 100% of the clinical and regulatory risk, while advancing the development of these late-stage assets.
Avillion was founded in 2012 in London, UK, and is backed by Abingworth, Clarus Ventures and Royalty Pharma. http://www.avillionllp.com
Allison Jeynes-Ellis, CEO
Mark Swallow, Citigate Dewe Rogerson
SOURCE Avillion LLP